News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Emergent BioSolutions 4Q Profit Plunges
March 6, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Emergent BioSolutions Inc. said Thursday its fourth-quarter profit plunged on a delay in deliveries of its anthrax vaccine BioThrax.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Emergent BioSolutions
MORE ON THIS TOPIC
Cancer
Sellas’ cancer vaccine slashes death risk by 41% in late-stage AML study
November 17, 2026
·
2 min read
·
Gabrielle Masson
Licensing
Lilly pens another deal, inking up to $5.9B oncology pact with Stipple
November 17, 2026
·
1 min read
·
Annalee Armstrong
Earnings
Genetix’s genetic medicines are officially profitable, with $327M in sales YTD
November 17, 2026
·
3 min read
·
Annalee Armstrong
Funding
Marrow Therapeutics debuts with $173M to tackle blood disorders in vivo
November 17, 2026
·
2 min read
·
Gabrielle Masson